There has been increasing awareness of antibody-mediated rejection (AMR) as an important cause of graft failure after lung transplantation in recent years. However, the diagnostic criteria for pulmonary AMR are not well defined. All four tenets of AMR in kidney and heart transplantation, graft dysfunction, complement component deposition, circulating donor-specific antibodies (DSA), and histopathologic changes consistent with AMR are infrequently present in lung transplantation. Nonetheless, the lung transplant community has made important progress recognizing cases of AMR and developing a definition. However, AMR is often refractory to therapy resulting in graft failure and death. In this review, we discuss the progress and challenges in the diagnosis and therapeutic options for pulmonary AMR. In addition, we briefly examine emerging paradigms of C4d-negative AMR and chronic AMR and conclude that significant progress is needed to mitigate the effects of humoral immune responses after lung transplantation.

Original languageEnglish
Pages (from-to)316-323
Number of pages8
JournalCurrent Transplantation Reports
Issue number4
StatePublished - Dec 1 2015


  • Autoimmunity
  • Complement C4d
  • Donor selection
  • Graft rejection
  • HLA antigens
  • Lung transplantation


Dive into the research topics of 'Antibody-Mediated Rejection in Lung Transplantation'. Together they form a unique fingerprint.

Cite this